Ustekinumab beats placebo for ulcerative colitis
![subcutaneous biologic](https://www.ausdoc.com.au/wp-content/uploads/2022/08/stomach_injection_biologic_dreamstime_m_53132622-1.jpg)
Patients with moderate to severe ulcerative colitis are more likely to achieve clinical remission and a range of other outcomes on ustekinumab than placebo, according to the results of a phase 3 trial.
In the pharma-company funded trial (known as UNIFI), 961 patients from 244 international sites were randomised to one of two different intravenous doses of a single, induction infusion of the drug or IV placebo.